0HL9Affimed N.V.

LSE · GB · Healthcare · Biotechnology · affimed.com

0.0001USDMkt Cap: —P/E: —6d ago

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has comple…

Key Statistics

Company

Market Cap—

Enterprise Value-11.21M $

Revenue (TTM)5.64M $

Gross Profit5.64M $

Net Income (TTM)-69.97M $

Revenue/Share0.3660 USD

Last Price0.0001 USD

Fiscal Year EndDec 2023

MR QuarterSep 2024

Employees76

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA0.18

EV/Revenue-1.99

P/S—

P/B0.00

EPS (TTM)-0.66

EPS (Forward)—

52W Range

—

52W High0.0001 USD

52W Low0.0001 USD

Profitability

Gross Margin100.00%

Oper. Margin-8709.15%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-149.49%

ROA-49.42%

Growth

Revenue Growth-91.60%

Earnings Growth—

Cash Flow & Leverage

Operating CF-76.90M $

CapEx (TTM)—

FCF Margin-805.14%

FCF Yield—

Net Debt-11.21M $

Net Debt/EBITDA0.18

Balance Sheet

Debt/Equity74.96

Current Ratio1.93

Quick Ratio1.71

Book Value/Sh1.226 USD

Cash/Share1.470 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split0.1:1

Split DateMar 11, 2024

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float15.48M

Insiders0.00%

Institutions0.00%

Technical

SMA 505.510 (-100.0%)

SMA 2005.863 (-100.0%)

Beta0.30

S&P 52W Chg19.18%

Avg Vol (30d)565

Avg Vol (10d)1.15K

Technical Indicators

RSI (14)47.8

MACD-0.0000

MACD Signal-0.0000

MACD Hist.+0.0000

BB Upper0.0002 USD

BB Middle0.0001 USD

BB Lower0.0000 USD

BB Width162.08%

ATR (14)0.0000 USD

Vol Ratio (20d)0.41x

0HL9Affimed N.V.

Industry Peers

Key Statistics